Retinal Vein Occlusion - Pipeline Review, H1 2017

  • ID: 4311877
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addmedica SAS
  • Aerpio Therapeutics Inc
  • Clearside BioMedical Inc
  • Formycon AG
  • Kala Pharmaceuticals Inc
  • Lupin Ltd
  • MORE
Retinal Vein Occlusion - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2017, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 1, 8 and 2 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addmedica SAS
  • Aerpio Therapeutics Inc
  • Clearside BioMedical Inc
  • Formycon AG
  • Kala Pharmaceuticals Inc
  • Lupin Ltd
  • MORE
  1. Introduction
  2. Retinal Vein Occlusion - Overview
  3. Retinal Vein Occlusion - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Retinal Vein Occlusion - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Retinal Vein Occlusion - Companies Involved in Therapeutics Development
  13. Addmedica SAS
  14. Aerpio Therapeutics Inc
  15. Chengdu Kanghong Pharmaceuticals Group Co Ltd
  16. Clearside BioMedical Inc
  17. Formycon AG
  18. Kala Pharmaceuticals Inc
  19. Lupin Ltd
  20. Mabion SA
  21. Ocular Therapeutix Inc
  22. Ohr Pharmaceutical Inc
  23. ThromboGenics NV
  24. Retinal Vein Occlusion - Drug Profiles
  25. aflibercept biosimilar - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. aflibercept biosimilar - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. AKB-9778 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. bevacizumab SR - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. conbercept - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. HO-10 - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. hydroxyurea - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. KPI-285 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. LKA-651 - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. ocriplasmin - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. OTX-TKI - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. Protein to Inhibit VEGF for Ophthalmology - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. ranibizumab biosimilar - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. ranibizumab biosimilar - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. ranibizumab biosimilar - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. squalamine lactate - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. triamcinolone acetonide - Drug Profile
  90. Product Description
  91. Mechanism Of Action
  92. R&D Progress
  93. Retinal Vein Occlusion - Dormant Projects
  94. Retinal Vein Occlusion - Discontinued Products
  95. Retinal Vein Occlusion - Product Development Milestones
  96. Featured News & Press Releases
  97. Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion
  98. Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
  99. Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
  100. Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
  101. Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
  102. Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
  103. Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
  104. Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
  105. Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
  106. Appendix
  107. Methodology
  108. Coverage
  109. Secondary Research
  110. Primary Research
  111. Expert Panel Validation
  112. Contact Us
  113. Disclaimer
List of Tables:
  1. Number of Products under Development for Retinal Vein Occlusion, H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1
  9. Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics Inc, H1
  10. Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1
  11. Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H1
  12. Retinal Vein Occlusion - Pipeline by Formycon AG, H1
  13. Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals Inc, H1
  14. Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1
  15. Retinal Vein Occlusion - Pipeline by Mabion SA, H1
  16. Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1
  17. Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H1
  18. Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1
  19. Retinal Vein Occlusion - Dormant Projects, H1
  20. Retinal Vein Occlusion - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Retinal Vein Occlusion, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Top 10 Targets, H1
  4. Number of Products by Stage and Top 10 Targets, H1
  5. Number of Products by Top 10 Mechanism of Actions, H1
  6. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addmedica SAS
  • Aerpio Therapeutics Inc
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • Formycon AG
  • Kala Pharmaceuticals Inc
  • Lupin Ltd
  • Mabion SA
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • ThromboGenics NV
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll